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ALSPACBackground: Psychosis and type 2 diabetes mellitus (T2DM) are commonly comorbid andmay share pathophys-
iologicmechanisms. To investigate shared genetic variation and inflammation aspotential commonmechanisms,
we tested: (i) associations between genetic predisposition for T2DM and psychotic experiences and psychotic
disorder in young adults; (ii) the association between genetic predisposition for schizophrenia and insulin resis-
tance (IR), a precursor of T2DM; and (iii) whether these associations are mediated by childhood inflammation.
Methods: Psychotic experiences (PEs), psychotic disorder and IR were assessed at age 18. Polygenic risk scores
(PRS) for T2DM and schizophrenia were derived based on large genome-wide association studies. Associations
between PRS and psychotic/IR outcomeswere assessed using regression analysis based on 3768 ALSPACbirth co-
hort participants with complete data. Inflammatory markers C-reactive protein (CRP) and interleukin 6 (IL-6)
measured at age 9 were used in regression and mediation analyses.
Results: Genetic predisposition for T2DM was associated with PEs (adjusted OR = 1.21; 95% CI, 1.01–1.45) and
psychotic disorder (adjusted OR = 1.51; 95% CI, 1.04–2.03) at age 18 in a linear dose-response fashion. Genetic
predisposition for schizophrenia was weakly associated with IR (adjusted OR= 1.10; 95% C·I, 0.99–1.22) at age
18. The association between genetic risk for T2DM and PEs was partly mediated by childhood CRP (p= .040).
Conclusions: Comorbidity between psychosis and T2DMmay be partly underpinned by shared genes and inflam-
mation. A summation of minor genetic variation representing lifetime risk for T2DM at conception may predis-
pose individuals to psychosis in adulthood by influencing physiologic changes, such as low-grade
inflammation, detectable as early as childhood.
© 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Reduced life-expectancy in schizophrenia is largely attributable to
physical comorbidity including cardiometabolic disorders, which are
up to 30%more prevalent in people with schizophrenia than in the gen-
eral population (Holt et al., 2004) (Lappin et al., 2018). Compared with
controls, markers of abnormal glucose-insulin homeostasis are two to
three times higher in young people with psychotic experiences (PEs)
(Perry et al., 2018), and in medication-naive first-episode psychosisry Research Group, Department
ith Building, Robinson Way,
.
. This is an open access article under
s, T.G. Richardson, et al., Com
arch, https://doi.org/10.1016(FEP) (Perry et al., 2016; Pillinger et al., 2017) after controlling for an-
thropometric and sociodemographic factors. This suggests that in-
creased T2DM in patients with psychosis may not be fully explained
by common lifestyle factors or side-effects of antipsychotic drugs,
though may be exacerbated by them (Rajkumar et al., 2017).
One contributor to comorbidity between cardiometabolic disorders
and schizophrenia could be shared genetic susceptibility (Lin and
Shuldiner, 2010). Risk of insulin resistance (IR) (Chouinard et al.,
2019) and impaired glucose tolerance (Ferentinos and Dikeos, 2012),
two key precursors of T2DM, are higher in unaffected relatives of pa-
tients with psychosis compared with controls. People with comorbid
schizophrenia and T2DM have a higher genetic predisposition for both
disorders compared to controls (Hackinger et al., 2018), and an associa-
tion between genetic predisposition for schizophrenia and IR has beenthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
mon mechanisms for type 2 diabetes and psychosis: Findings from a
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2 B.I. Perry et al. / Schizophrenia Research xxx (xxxx) xxxreported in a clinical sample (Tomasik et al., 2019). Conversely, a rela-
tively small study found no evidence of an association between genetic
risk for T2DM and psychosis (Padmanabhan et al., 2016), and previous
research using linkage-disequilibrium (LD) score regression found lim-
ited evidence for a genetic correlation between schizophrenia and
T2DM (Bulik-Sullivan et al., 2015). However, a key feature of existing
studies is that they are based on adult cases of established schizophrenia
or T2DM or rely on blood measurements taken in adulthood, so con-
founding by cumulative effects of lifestyle and other factors is possible
(Reinikainen et al., 2015). Population-based prospective studies have
identified early markers of disease risk associated with T2DM and
schizophrenia. For instance, PEs in adolescence or young adulthood
are associated with risk of schizophrenia in adulthood (Poulton et al.,
2000; Zammit et al., 2013), and IR is a precursor of T2DM (Martin
et al., 1992). To our knowledge, no studies have examined whether ge-
netic predispositions for T2DMor schizophrenia are associatedwith, re-
spectively, PEs or IR, in young adulthood. Demonstrating such
associations with early markers of illness in young adults with lessened
effects of cumulative lifestyle confoundingwould be consistentwith the
idea that shared genetic variation is a common mechanism for comor-
bid T2DM and schizophrenia.
Although existing studies provide some evidence for a shared ge-
netic basis for T2DM and schizophrenia, underlying pathophysiologic
mechanisms remain unclear. Low-grade inflammation may be one
such mechanism, which has been reported to be associated with IR
(Festa et al., 2000), T2DM (Pradhan et al., 2001) and psychosis
(Upthegrove et al., 2014). Population-based longitudinal studies report
that higher levels of circulating inflammatory markers at baseline are
associatedwith risks of psychosis and abnormal glucose-insulin homeo-
stasis subsequently at follow-up (Khandaker et al., 2014; Perry et al.,
2018). Mendelian randomisation (MR) studies have reported associa-
tions of genetic variants regulating inflammatory biomarkers such as
interleukin-6 (IL-6) with schizophrenia (Hartwig et al., 2017), suggest-
ing that inflammation may be associated with schizophrenia beyond
any effects of confounding. Inflammation has also been implicated in
the pathogenesis of IR and T2DM (Pradhan et al., 2001).
We examined whether shared genetic variation and inflammation
could be common mechanisms for T2DM and psychosis using prospec-
tive, population-based data from the ALSPAC birth cohort. We tested
whether: (i) genetic predisposition for T2DM is associated with risk of
PEs and psychotic disorder at age 18; (ii) genetic predisposition for
schizophrenia is associated with IR at age 18; (iii) whether these associa-
tions are mediated by CRP or IL-6 levels measured in childhood at age 9.
2. Methods
2.1. Description of cohort and sample selection
The ALSPAC birth cohort (Boyd et al., 2013; Fraser et al., 2013) com-
prises 14,062 live births from mothers residing in former County Avon
in Southwest England, with expected dates of delivery between April
1991 and December 1992 (http://www.bristol.ac.uk/alspac/
researchers/our-data/). The study received ethics approval from the
ALSPAC Ethics and Law Committee and local research ethics commit-
tees. All participants provided written or implied informed consent. In
total, 7977 participants had genotyping data, 3768 participants had
data onboth genotyping andpsychosis outcomes, and 2344participants
had data on genotyping and IR (Supplementary Fig. 1). Our analysis was
conducted on participants without missing data for the covariates or
outcomes of interest.
2.2. Assessment of psychotic outcomes at age 18
2.2.1. Psychotic experiences (PEs)
PEs were identified through the face-to-face, semi-structured
Psychosis-Like Symptom Interview (PLIKSi) conducted by trainedPlease cite this article as: B.I. Perry, H.J. Jones, T.G. Richardson, et al., Com
prospective birth cohort, Schizophrenia Research, https://doi.org/10.1016psychology graduates. The PLIKSi comprised of an introductory set of
questions on unusual experiences, and then 12 ‘core’ questions eliciting
key symptoms covering the three main domains of positive psychotic
symptoms: hallucinations (visual and auditory); delusions (delusions
of being spied on, persecution, thoughts being read, reference, control,
grandiose ability and other unspecified delusions); and symptoms of
thought interference (thought broadcasting, insertion andwithdrawal).
For these 12 core items, 7 stem questions were derived from the Diag-
nostic Interview Schedule for Children–IV (DISC–IV) and 5 stems from
section 17–19 of the Schedules for Clinical Assessment in Neuropsychi-
atry version 2.0 (SCAN 2.0). After cross-questioning, interviewers rated
PEs as not present, suspected, or definitely present. Interviewers rated
down (i.e. suspected rather than definite, or none rather than
suspected) if unsure. For suspected or definite PEs, interviewers also re-
corded the frequency; effects on social/educational/ occupational func-
tion; help seeking; and attributions including fever, hypnopompic/
hypnogogic state, or illicit drugs. For interrater reliability, the inter-
viewers recorded audio interviews at three time points, approximately
6 months apart, across the clinic duration (75 interviews in total). The
average kappa value of PEs was 0.83, with no evidence of differences
across time. Test-retest reliability was assessed using 162 individuals
reinterviewed after approximately 47 days (kappa = 0.76, SE =
0.078), 46 of whom were reinterviewed by the same interviewer
(kappa= 0.86, SE= 0.136). Our primary outcomewas presence of def-
inite PEs, referring to at least one definite PE since age 12; the compar-
ator group was suspected/no PEs. Our outcome is reflective of 6-year
period prevalence of definite PEs. From the total number of participants
with definite PEs at 18y (230, 4.9%), 80 participants (45.3%) had suffered
definite PEs at least once in the month preceding assessment. From the
total sample of participants reporting definite PEs, 146 participants
(63.5%) reported auditory hallucinations, 63 participants (28.2%) re-
ported any delusion, and 22 participants (9.9%) reported thought dis-
turbance. See Supplementary Table 1 for full frequency data,
Supplementary Table 2 for information on timing of onset of PEs, and
the main reporting study for further information (Zammit et al., 2013).
2.2.2. Psychotic disorder
Psychotic disorderwas defined (Zammit et al., 2013) as the presence
of PEs when symptoms were not attributable to fever/sleep/drugs, had
occurred at least once per month over the previous 6 months, and
caused significant distress resulting in either help-seeking from a pro-
fessional source (general practitioner, counsellor, mental health team),
or significantly disrupted social/occupational function. From the total
ALSPAC sample who underwent the PLIKSi, 46 participants (1.0%) met
criteria for psychotic disorder. We included psychotic disorder as a sec-
ondary outcome due to its lower prevalence in the study sample.
2.3. Assessment for a T2DM-risk outcome at age 18
2.3.1. Insulin resistance
IR was calculated as a binary variable based on fasting plasma glu-
cose and insulin levels at age 18, using the well-validated homeostasis
model assessment (HOMA) method (Matthews et al., 1985). There is
no consensus-agreed cut-off for clinical IR in the literature since levels
can vary between populations (Wallace et al., 2004). Therefore, we
used the 75th centiles of the study population to define IR. The 75th
centile cut-off has been used in previous research (Cediel et al., 2016;
Geloneze et al., 2006; Hedblad et al., 2000; Marques-Vidal et al.,
2002). The 75th centile in our study population was 2.15.
2.4. Assessment for polygenic risk scores for T2DM and schizophrenia
From the ALSPAC cohort, 8812 participants were genotyped using
the Illumina HumanHap550 quad genome-wide SNP genotyping plat-
formby 23andMe subcontracted to theWellcome Trust Sanger Institute,
Cambridge, UK and the Laboratory Corporation of America, Burlington,mon mechanisms for type 2 diabetes and psychosis: Findings from a
/j.schres.2020.08.006
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restricting to 1 young person per family, genetic data was available for
7977 ALSPAC individuals. See Supplementary Methods for further
information.
Polygenic risk scores (PRS) for schizophrenia and T2DM were con-
structed for all 7977 participants with genotype data, using training
sets based on the second Psychiatric Genomics Consortium (PGC)
Schizophrenia GWAS (Schizophrenia Working Group of the
Psychiatric Genomics Consortium, 2014) and a large T2DM GWAS
(Mahajan et al., 2014), respectively. Both GWAS analyses adjusted for
principal components to reduce the impact of population stratification
(Price et al., 2006). PRS were calculated using the PLINK (v1.9) (Chang
et al., 2015; Purcell et al., 2007) ‘score’ command following themethod-
ology described by the International Schizophrenia Consortium (ISC)
(Purcell et al., 2009). Prior to construction of scores, single nucleotide
polymorphisms (SNPs) were removed from the analysis if they had a
minor allele frequency less than 0.01, an imputation quality less than
0.8 or if there was allelic mismatch between samples (see Supplemen-
tary methods for details). Due to the presence of strand differences be-
tween ALSPAC and the T2DM GWAS, and lack of allele frequency
information in the T2DM summary statistics, palindromic SNPs were
also removed prior to construction of the T2DM PRS. Because of the
high linkage disequilibrium (LD) within the extended major histocom-
patibility complex (MHC; chromosome 6: 25-34 Mb) only a single SNP
was included to represent this region. SNPs were pruned for LD using
the PLINK ‘clump’ command to remove SNPs in LD (r2 > 0.25) with a
more significant SNP in the training set. Windows of 500 kb were
used to assess inter-SNP LD for pruning.
For the primary analysis, PRS were constructed using a list of SNPs
with the optimal p-value thresholds to capture phenotypic variance de-
fined by both GWAS individually (p ≤ 10−5 for T2DM (Mahajan et al.,
2014) and p ≤ .05 for schizophrenia (Schizophrenia Working Group of
the Psychiatric Genomics Consortium, 2014)). Scores were weighted
by the logarithm of the odds ratio (OR) for schizophrenia or T2DM re-
ported by the GWAS training sets, for the schizophrenia and T2DM
PRS, respectively. 10 Principal components (PCs) were generated
using unrelated individuals (IBS < 0.05) and independent SNPs (with
long range LD regions removed) using the `– pca` command in
PLINK1.90. All PRS analyses were adjusted for the 10 PCs to reduce the
risk of population stratification. Two PRS measures were calculated for
T2DM; the first including all SNPs associated with T2DM, and the sec-
ond after excluding a SNP located in the FTO gene region, which is
widely understood to be associated with T2DM only through its influ-
ence on bodymass index (BMI) variation (Frayling et al., 2007); the lat-
ter was used in sensitivity analysis. Additionally, since the optimal p-
value thresholds of both PRS scores differed, we conducted sensitivity
analyses to examine PRS-outcome associations using a range of p-
value thresholds from p = .5 to genome-wide significance
(p < 5 × 10−8).2.5. Assessment of inflammatory markers at age 9
Data on two inflammatory markers at age 9 years (IL-6 and CRP)
were available in ALSPAC, for 5076 and 5086 participants respectively.
Blood samples were collected at non-fasting state. Please see supple-
mentary methods for further information.2.6. Assessment of potential confounders
We included sex (categorical), ethnicity (binary caucasian/non-
caucasian due to the predominantly caucasian sample), social class (cat-
egorical) and BMI at age 18 years (continuous). We excluded partici-
pants with hsCRP levels >10 mg/L to minimize potential bias from
recent/ongoing infection or chronic inflammatory disease.Please cite this article as: B.I. Perry, H.J. Jones, T.G. Richardson, et al., Com
prospective birth cohort, Schizophrenia Research, https://doi.org/10.10162.7. Statistical analysis
We examined the distribution of PRS-T2DM and PRS-schizophrenia
using the Shapiro-Wilk test for normality, and from visual inspection of
Q-Q plots. The distributions were p > .05 and appeared normally dis-
tributed. Both PRS variables were standardized (Z-transformed).
2.7.1. Association between PRS and outcomes at age 18
We conducted logistic regression analyses to examine the associa-
tion between PRS-T2DM and risks for PEs and psychotic disorder, and
PRS-schizophrenia and IR at age 18. The odds ratios (OR) and 95% con-
fidence intervals (95% C.I.) indicate increase in risk per standard devia-
tion (SD) increase in PRS. Regression models were adjusted for sex,
ethnicity, social class, and BMI. p-values for adjusted regression models
in our primary analysis were corrected formultiple testing per the three
outcomes we included (definite PEs, psychotic disorder and IR) using
the Holm-Bonferroni method (Holland and Copenhaver, 1987). We
used the p.adjust() command in R (R Core Team, 2017) to perform ad-
justments. In results tables, we present the original unadjusted p-
values alongside Holm-Bonferroni adjusted p-values. To test for linear-
ity of associations, we included a quadratic term (PRS2) in the logistic
regression models.
2.7.2. Association between PRS scores and childhood inflammatorymarkers
at age 9 years
We used linear regression analyses to test associations of PRS for
T2DM or schizophrenia, separately, with IL-6 and CRP levels at age
9 years (Z-transformed values), before and after adjustments for poten-
tial confounders listed above.
2.7.3. Mediation by childhood CRP
We performed mediation analyses to examine whether any evident
associations may be mediated by childhood CRP levels. We calculated
direct and indirect effects between exposure (PRS-T2DM or PRS-
schizophrenia) and outcome (e.g., PEs or IR) taking into account theme-
diator variable (e.g., CRP). Evidence of an indirect effect is consistent
with mediation. The indirect effect was bootstrapped using 5000 itera-
tions to determine the 95% CIs. Mediation analysis was performed
using the PROCESS macro V3.1 for IBM SPSS 24.0 (http://www.
afhayes.com).
2.8. Missing data
We assessed the potential impact of missing data by comparing
mean PRS score between the analytic sample and participants with
missing data for psychosis and IR outcomes, using separate variance t-
tests. We also performed logistic regression analysis to determine
sociodemographic and other predictors (sex, ethnicity, BMI and social
class) of missing data.
3. Results
3.1. Baseline characteristics of sample
Of the 3768 participants with data on PRS-T2DM and psychotic out-
comes, 283 met the criteria for suspected/definite PEs (7.5%), 183 for
definite PEs (5.1%), 29 (0.7%) for psychotic disorder at age 18
(Table 1). Of the 2344 participants with data on PRS-schizophrenia
and IR, 173 met the criteria for IR at age 18 (7.3%).
3.2. Association between genetic predisposition for T2DM and psychotic
outcomes at age 18
The prevalence of psychotic outcomes at age 18 years was higher for
participants in the top third of PRS-T2DM distribution compared with
those in the bottom third (Fig. 1). PRS-T2DM was associated withmon mechanisms for type 2 diabetes and psychosis: Findings from a
/j.schres.2020.08.006
Table 1
Baseline characteristics of sample.
Characteristic, n (%) unless otherwise stated All sample Definite PEs Psychotic disorder No/suspected PEs
Male sex 1846 (49) 71 (38) 7 (15) 1775 (49)
White British ethnicity 3692 (98) 179 (98) 39 (95) 3513 (98)
Social class
I & II 1582 (42) 62 (35) 5 (16) 1456 (40)
III - non manual & manual 1616 (43) 75 (43) 15 (48) 1630 (44)
IV & V 565 (15) 38 (22) 11 (36) 583 (16)
BMI (kg/m2) at 18 years, mean (SD) 22.71 (3.76) 23.37 (4.49) 22.73 (4.26) 22.60 (3.71)
HOMA at 18 years, mean (SD) 0.92 (0.73) 1.03 (0.75) 1.28 (1.00) 0.92 (0.73)
Insulin resistance 251 (8) 25 (17) 7 (20) 209 (7)
Current smoking 220 (7) 22 (15) 5 (18) 188 (7)
CRP (mg/L) at 9 years, mean (SD) 0.68 (2.52) 0.72 (2.61) 0.75 (1.33) 0.67 (2.49)
PEs attributed to sleep/fever/drugsa N/A 31 (0.7) 7 (0.1) 27 (0.6)
Help-seeking from professional sourcea N/A 55 (24) 41 (51.9) 6 (3)
Information based on total ALSPAC sample.
a Recorded from Zammit et al. (2013).
4 B.I. Perry et al. / Schizophrenia Research xxx (xxxx) xxxdefinite PEs (adjusted OR = 1.21; 95% CI, 1.01–1.45 per SD increase in
PRS-T2DM) and psychotic disorder (adjusted OR = 1.51; 95% CI,
1.04–2.05 per SD increase in PRS-T2DM) at age 18 years after control-
ling for sex, ethnicity, social class and BMI (Table 2). Quadratic terms
for PRS-T2DM in these regressionmodels were non-significant suggest-
ing no evidence for departure from linearity (all p> .05). The results for
sensitivity analyses using PRS-T2DM score excluding a SNP in the FTO
gene region were similar (Supplementary Table 3).
3.3. Association between genetic predisposition for schizophrenia and IR at
age 18
There was weaker evidence for an association between PRS-
schizophrenia and IR at age 18 (adjusted OR = 1.10; 95% CI, 0.99–1.22
per SD increase in PRS-schizophrenia) after controlling for sex, ethnic-
ity, social class and BMI. The quadratic term for PRS-schizophrenia
was non-significant suggesting no evidence for departure from linearity
(p > .05).
3.4. Associations between PRS scores and inflammatory markers at age 9
Data on both PRS scores and serum IL-6 and CRP levels were avail-
able for 2180 and 2176 participants respectively. After adjustments for
sex, ethnicity, social class and BMI, PRS-T2DM was associated with
CRP (β= 0.03; 95% CI, 0.01–0.08, p = .040), but not with IL-6 (β=
0.01; 95%CI,−0.02–0.05, p=.082). Therewas also trend level evidenceFig. 1. Prevalence of psychotic experiences and psych
Please cite this article as: B.I. Perry, H.J. Jones, T.G. Richardson, et al., Com
prospective birth cohort, Schizophrenia Research, https://doi.org/10.1016for an association between PRS-schizophrenia and CRP (β= 0.05; 95%
CI,−0.01–0.10, p= .061) but not with IL-6 (β= 0.01; 95% CI,−0.04-
0.09, p= .670).
3.5. Mediating effect of childhood CRP levels on the associations of PRS
scores with psychotic outcomes or IR
Based on 1955 participants with data on PRS-T2DM, CRP levels at
age 9 and PEs at age 18, CRP at age 9 partially mediated the association
betweenPRS-T2DMand definite PEs at age 18. Therewas evidence of an
indirect effect indicative of mediation; the coefficients were 0.28; 95%
CI, 0.07–0.45, p = .044 for direct effect; co-efficient = 0.05; 95% CI
0.02–0.12, p = .040 for indirect effect. Since IL-6 levels at age 9 years
were not associated with PRS-T2DM, we did not perform mediation
analysis using IL-6. There was no evidence for a mediating effect of
CRP on the association between PRS-schizophrenia and IR at age 18;
the coefficients were 0.14; 95% CI,−0.06–0.34, p = .756 for direct ef-
fect; co-efficient = 0.01; 95% CI, −0.01–0.03, p = .180 for indirect
effect.
3.6. Results for sensitivity analysis using different P-value thresholds for PRS
Fig. 2 presents the associations between PRS-T2DM and PEs along-
side the associations between PRS-schizophrenia and IR, at different
PRS p-value thresholds. The point estimates for the PRS-T2DM-PEs asso-
ciations were >1 for all p-value thresholds, though the strength ofotic disorder at age 18 per tertile of PRS-T2DM.
mon mechanisms for type 2 diabetes and psychosis: Findings from a
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Table 2
Odds ratios (95% CI) for outcomes at age 18 per SD increase in polygenic risk score for T2DM or schizophrenia.
Outcome/risk factor Sample OR (95% C.I.) p-value Corrected p-valuec
Unadjusteda Adjusted for sex, ethnicity, social class and BMIb
Definite PEs
PRS-T2DM 3768 1.15 (0.99–1.34) 1.21 (1.01–1.45) 0.027 0.054
Psychotic disorder
PRS-T2DM 3768 1.42 (1.00–1.96) 1.51 (1.04–2.05) 0.016 0.048⁎
Insulin resistance
PRS-SCZ 2344 1.16 (1.04–1.32) 1.10 (0.99–1.22) 0.089 0.089
a Unadjusted analysis adjusted for 10 principal components only.
b Samples for adjusted analysis included 3070 participants for psychotic outcomes and 1970 participants for insulin resistance outcome.
c p-value corrected from adjusted analysis using Holm-Bonferroni method.
⁎ Evidence surpasses Holm-Bonferroni threshold.
5B.I. Perry et al. / Schizophrenia Research xxx (xxxx) xxxassociation weakened at more stringent p-value thresholds. A similar
pattern was observed for the PRS-schizophrenia-IR association, where
the evidence for a positive association attenuated at p-value thresholds
more stringent than 1.00 × 10−4.
3.7. Missing data
Fifty-three percent of participants with data on PRS-T2DM had psy-
chotic outcomes data missing, and 71% of participants with PRS-
schizophrenia had IR outcome data missing (Supplementary Fig. 1).
Compared with the analytic sample, the missing sample had higher
mean PRS-schizophrenia but lower PRS-T2DM scores (Supplementary
Table 4). Male sex, lower social class and higher BMI predicted missing
data for psychotic outcomes, and non-white ethnicity was associated
with having missing data for IR (Supplementary Table 5).
4. Discussion
4.1. Main findings and comparisons with the literature
Usingprospective birth cohort data,we report that genetic predispo-
sition for T2DM is associatedwith psychotic outcomes at age 18 in a lin-
ear fashion. The PRS-T2DM findings were consistent using two genetic
scores; onewith and onewithout a SNP at the FTO locus, which is under-
stood to be related to BMI (Frayling et al., 2007). Additionally, therewas
evidence for a dose-response pattern in the association between PRS-
T2DM and psychotic outcomes; the effect size was strongest for psy-
chotic disorder, which is a more clinically relevant outcome than PEs.
We also report some evidence, albeit slightly weaker, for an associationFig. 2. Association between PRS score and outcome at
Please cite this article as: B.I. Perry, H.J. Jones, T.G. Richardson, et al., Com
prospective birth cohort, Schizophrenia Research, https://doi.org/10.1016between genetic predisposition for schizophrenia and IR at age 18.
However, the sample of participants with missing data had higher
mean PRS-schizophrenia scores than included participants, thus miss-
ing data may help to at least partly explain the weaker evidence. None-
theless, our findings provide some evidence that the comorbidity
between T2DM and schizophrenia arises partly due to shared genetic
factors.
The point estimates across various p-value thresholds for T2DM and
schizophrenia were similar in both combinations of genotype-
phenotype analysis, though in both cases at more stringent p-value
thresholds, the evidence of associationweakened. Thisweakeningeffect
is consistent with a previous study examining the association between
PRS-schizophrenia and adolescent psychopathology (Jones et al.,
2016), which also reported that PRS-schizophrenia was associated
with attrition. Therefore, type II statistical error may be one explanation
for the weaker associations between PRS-schizophrenia and IR.
Our results are in line with one previous study in a relatively large
sample, which found that people with comorbid schizophrenia and
T2DM have a higher genetic predisposition to both disorders compared
to controls (Hackinger et al., 2018), and another recent report of an as-
sociation between PRS for schizophrenia and IR in a clinical sample of
people with schizophrenia (Tomasik et al., 2019). Another study found
evidence for a genetic overlap between schizophrenia and both triglyc-
erides and HDL (Andreassen et al., 2013), which are cardiometabolic in-
dices known to be tightly linked with an insulin resistance phenotype
(Laws and Reaven, 1992), alongside other cardiometabolic factors in-
cluding systolic blood pressure, BMI and waist: hip ratio. One previous
study however found no evidence for an association between PRS-
T2DM and schizophrenia (Padmanabhan et al., 2016), though the latterage 18 years at different PRS P-value thresholds.
mon mechanisms for type 2 diabetes and psychosis: Findings from a
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therefore have been underpowered to detect a difference. Another
study using LD-score regression (Bulik-Sullivan et al., 2015) found lim-
ited evidence for a genetic correlation between schizophrenia and
T2DM, though the latter study was based on older and less-powered
GWAS for both disorders. However, the same study did find some evi-
dence for genetic correlation between schizophrenia and BMI, and, an-
other recent study provides some evidence for shared genetic loci
between BMI and mental disorders including schizophrenia (Bahrami
et al., 2020). In future, genetic studies may seek to examine the associa-
tion between PRS scores for other cardiometabolic traits in their associ-
ation with schizophrenia and other mental disorders.
It is also possible that genetic-risk for T2DMor schizophreniamay in-
crease the risk of both disorders via pleiotropic mechanisms. This may
help to explain the differences in our results compared with genetic cor-
relation analyses (Bulik-Sullivan et al., 2015). For example, it is possible
that genetic-risk for schizophrenia may predispose to adverse experi-
ences in childhood, which could in t urn influence inflammation
(Slopen et al., 2013). We found some evidence for the association of
childhood CRP levelswith both PRS-T2DMand PRS-schizophrenia. How-
ever, we did notfind an associationwith IL-6. This is perhaps unexpected
since IL-6 stimulates the production of CRP (Calabro et al., 2003), and is
associated with both psychotic outcomes (Khandaker et al., 2014) and
IR (Kim et al., 2009). However, it is also possible that genetic predisposi-
tion for T2DM or schizophrenia influences CRP via mechanisms other
than IL-6. CRP has been shown to play an active role in hepatic insulin re-
sistance, at least partly through impairment in insulin signalling, inde-
pendent of IL-6 (Xi et al., 2011). Interestingly, CRP has shown to be
protective of schizophrenia in MR studies (Hartwig et al., 2017), how-
ever, theGWAS studies included in previousMR researchmeasured phe-
notypic markers in adults. We used CRP measured in childhood, which
may be reflective of a distinct biological environment.
We report some evidence that genetic predisposition for T2DMmay
influence risk of psychosis in early-adulthood by increasing inflamma-
tion in childhood, but the magnitude of this mediating effect was
small, suggesting that other mechanisms are likely to be involved. On
theother hand,we foundnoevidence that childhood IL-6/CRPmediated
the association between genetic predisposition for schizophrenia and
IR. The mediating effect of inflammation for the outcome of PEs is con-
sistentwith previous research reporting an association between genetic
risk for schizophrenia and immune-related disorders (Stringer et al.,
2014; Tylee et al., 2018). However, due to the relatively small number
of participants with psychotic disorder in our sample and associated
lack of power, we were unable to consider testing psychotic disorder
inmediation analyses. Future longitudinal research conducted on larger
samples of participantsmay seek to performamediation analysis of CRP
between PRS-T2DM and more clinically relevant psychotic outcomes.
Othermediators for PRS-T2DMand psychotic outcomesmay include
non-immunemechanisms such as pleotropic genes affecting distinct bi-
ological pathways relevant for each condition. For example, a study ex-
amining the genetic overlap between T2DM and schizophrenia
highlighted, among others, PROX1 as a potentially pleiotropic locus
(Hackinger et al., 2018). PROX1 acts both as a transcriptional activator
and repressor. It has been implicated in murine beta-cell development
as well as in neurogenesis in humans (Holzmann et al., 2015). Due to
the relatively small number of participants with psychotic disorder in
our sample and associated lack of power, we were unable to consider
testing psychotic disorder inmediation analyses. Future longitudinal re-
search conducted on larger samples of participantsmay seek to perform
amediation analysis of CRP between PRS-T2DM andmore clinically rel-
evant psychotic outcomes.
4.2. Strengths and limitations
In this study, we have examined the influence of genetic predisposi-
tions for T2DM and schizophrenia on, respectively, psychosis-risk andPlease cite this article as: B.I. Perry, H.J. Jones, T.G. Richardson, et al., Com
prospective birth cohort, Schizophrenia Research, https://doi.org/10.1016T2DM-risk using a prospective birth cohort. We provide some evidence
that a genetic basis may explain at least part of the variance of the com-
monly observed comorbidity between the two phenotypes. In addition,
we have used childhood inflammatorymarker data to test potentialme-
diating effects of inflammation for these associations. Since our expo-
sures were genetic risk, the potential for confounding by
environmental and lifestyle factors is limited. However, it is well
known that certain antipsychotic medications can have adverse effects
on glycaemic indices (Leucht et al., 2013). At present, ALSPAC does not
have treatment record linkage and we were thus unable to adjust for
antipsychotic treatment. This may have impacted our results for the
analyses examining PRS-schizophrenia and IR. We were able to control
for potential confounding effects of sex, BMI, social class and for inflam-
matory disease. Regarding ethnicity, participants of non-European ge-
netic ancestry were removed at the stage of genotyping analysis. We
also adjusted our regression analyses for ethnicity, since ethnicity is sig-
nificantly associated with T2DM-risk (Oldroyd et al., 2005). We further
adjusted for PCs (Price et al., 2006) in our PRS analyses, to further reduce
the risk of population stratification bias. By including PRS for schizo-
phrenia in our analyses, we help to address a common limitation of re-
search conducted on PEs, that they may not adequately capture
schizophrenia liability (Jones et al., 2016); the results of both sets of
analyses were consistent. A key limitation is missing data. Over half of
the risk set with data on PRS had outcome data missing at follow-up.
The missing sample had a higher mean score for PRS-schizophrenia
but a lowermean score for PRS-T2DM. Thus, our analysesmay underes-
timate the true association between genetic predisposition for schizo-
phrenia and IR, whilst the opposite might be the case for the
association between PRS-T2DM and psychotic outcomes. Furthermore,
whilst PEs and psychotic disorder have been shown to reflect an in-
creased risk for psychotic disorders (Sullivan et al., 2020; Zammit
et al., 2013), and PEs lie on a continuum with clinical psychosis in the
general population (van Os et al., 2009), our data do not allow us to de-
terminewhether peoplemeet criteria for specific psychotic disorders as
classified in DSM or ICD. The transition from PEs to clinical psychosis is
low (Kaymaz et al., 2012), PEs are also associated with other psychiatric
phenotypes such as depressive and anxiety disorders (Kelleher et al.,
2012), and previous research has found no evidence of an association
between PRS-schizophrenia and PEs (Jones et al., 2016). Additionally,
since our psychotic outcomes were measured prior to the peak age of
onset of clinical psychosis (Eranti et al., 2013), some participants may
not have yet developed psychotic symptoms or disorder. This point
also applies to our sample of participants meeting the criteria for IR at
age 18, since age 18may be relatively early for the phenotype to become
detectable. This may be a further explanation for the weaker evidence
for an association between PRS-schizophrenia and IR at age 18. Whilst
we attempted to address these limitations by reversing the genotype
and phenotype to more accurately capture schizophrenia/T2DM liabil-
ity, replication of our methods in an adequately powered clinical (and
likely older) sample of peoplewith clinically diagnosed psychotic disor-
ders such as schizophrenia, is necessary. Finally, one-off measurements
of inflammatory markers in childhood may not reflect lifelong levels of
inflammation. However, measurement error, if non-differential, intro-
duces a bias towards the null, so our results may underestimate the
true association between PRS-T2DM and IL-6 and CRP.
Future research may complement our work by employing genomic
advances which test a greater proportion of genomic information than
solely PRS scores, the latter of which are highly dependent on the
power of GWAS studies. Such methods might include colocalization
analysis (Giambartolomei et al., 2014) or locus-level genetic correlation
analysis (Shi et al., 2017). Such researchmay build on our own since re-
search conducted using PRS scores may be susceptible to type II error
due to the phenomenon of ‘missing heritability’, which is the difference
between the known heritability of a trait compared with the currently
identified risk-increasing variants (Manolio et al., 2009). It is likely
that at least some of the heritability of schizophrenia (Woo et al.,mon mechanisms for type 2 diabetes and psychosis: Findings from a
/j.schres.2020.08.006
7B.I. Perry et al. / Schizophrenia Research xxx (xxxx) xxx2017) as well as cardiometabolic disorders (Xia et al., 2016) lies in a
number of low-frequency, low-effect-size variants which are therefore
difficult to detect with current GWAS methods.4.3. Implications
Ourwork provides some evidence that, limitations notwithstanding,
a summation of minor genetic variation representing lifetime risk for
T2DM or schizophrenia at conception, may contribute a portion of the
variance of the comorbidity of these disorders in adulthood. Further-
more, we report that genetic predisposition for T2DM may increase
risk of PEs by influencing physiologic changes, such as low-grade in-
flammation, detectable as early as childhood. It is well known that
some commonly prescribed antipsychotics can cause or worsen cardio-
metabolic indices (Leucht et al., 2013), even after a relatively short
length of exposure (Neilsen et al., 2010). Therefore, clinicians who
look after people with schizophrenia should ascribe detailed attention
to the malleable risk factors for cardiometabolic disorders, such as
with the promotion of a healthy lifestyle (Teasdale et al., 2019; Ward
et al., 2017), and with careful selection and monitoring of antipsychotic
medications. This may help to reduce the excess cardiometabolic illness
relatedmorbidity andmortality in peoplewith schizophrenia. In future,
similar research may seek to examine the associations between PRS for
T2DMand othermental disorders including T2DMand bipolar disorder,
both of which are known to have higher rates of cardiometabolic disor-
ders than the general population (Martin et al., 2016). Such research
may also help to test the specificity of the findings in this study.Declaration of competing interest
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